Navigation Links
Researchers discover how malaria parasite disperses from red blood cells

ned the blood cells green, the other stained the parasites red.

In the first stage of the merozoites' release, which the researchers dubbed the "irregular schizont" stage, the red blood cell resembles a lop-sided fried egg, with the parasites visible as a sphere near the center of the cell. (A diagram of the entire sequence appears at http://www.nichd.nih.gov/new/releases/malaria_graphic.cfm.) The cell's lop-sided appearance probably results from destruction of the cytoskeleton, the molecular scaffolding that helps the cell to maintain its rounded shape.

In the next stage, called the "flower" stage, the red blood cell assumes a roughly spherical shape, covered with rounded structures that resemble the petals of a flower. Shortly thereafter, the blood cell's membrane appears to break apart. At roughly the same time, cellular compartments, called vacuoles, which encase the newly formed merozoites, also break apart. The entire process has an explosive appearance, dispersing the merozoites some distance from the cell.

During the release, Dr. Zimmerberg explained, the cell membrane appears to collapse inward upon itself and fragment into pieces.

One previous theory held that the red blood cells and the merozoite-containing vacuoles inside them swelled and then burst like a balloon containing too much air.

"The swelling was an artifact of too much light from the microscope," Dr. Zimmerberg said. "The cell membrane was light sensitive. When we turned the light down, we didn't see the swelling." Rather, he said, upon release of the merozoites, the cell membrane appeared to contract in upon itself.

Another theory held that the merozoite-containing vacuoles would fuse with the cell membrane, and then release their contents.

"But we didn't see any fusion," Dr. Zimmerberg said.

The third theory held that the cell membrane ruptured, ex
'"/>

Source:NIH/National Institute of Child Health and Human Development


Page: 1 2 3

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain

Post Your Comments:
(Date:11/30/2009)...s of The Journal of Experimental Biology are ple... National de la Recherche Scientifique (CNRS) in t...r of this year,s JEB Outstanding Paper Prize. ,T...ng achievement and is intended to encourage young ...-in-Chief, and adds that ,we truly appreciate when...
(Date:11/30/2009)...led invasion proteins are crucial for infection. E...man cells, which stimulates the host cell to take ...s exert a different function, for example the regu...,s results have now been published in the current ... Spoiled meat is one of the sources for Listeria ...
(Date:11/30/2009)...tage of lower early bird registration rates and re...ngress of 2010 at http://www.iofwco-ecceo10.org/ ... the International Osteoporosis Foundation (IOF) a...Aspects of Osteoporosis and Osteoarthritis (ESCEO)...ld are expected to attend. The exciting scientific...
Breaking Biology News(10 mins):French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4It takes 2 to infect 2Happier healthier more productive hens on omega 3 3F 9233 1Happier healthier more productive hens on omega 3 3F 9233 2Secure eHealth and DRM Security Partner to Provide Most Secure Healthcare Network Available 51456 1Secure eHealth and DRM Security Partner to Provide Most Secure Healthcare Network Available 51456 2Secure eHealth and DRM Security Partner to Provide Most Secure Healthcare Network Available 51456 3Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 1Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 2Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 3Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 4
...nternational clinical trial, a new drug that selec...tive in preventing acute kidney transplant rejecti...eatment. , Patients who took the experimental dru...29Y), also had better kidney function and experien... standard anti-rejection drugs, including kidney d...
...sts have tracked down the biological trigger that ...sfiguring bone disorder that can cause blindness a...g-range gene regulation and could lead to new trea...isorders. , A research team from Lawrence Livermor... Novartis Institutes for BioMedical Research in Sw...
...of the first molecular studies of the human antibo... Institute (HHMI) researchers and their colleagues... immune systems need to spot and quash this often-...p scientists improve the existing vaccine, which h...en, an HHMI international research scholar and ass...
Other Biology News:New type of rejection blocker protects kidneys after transplant 2New type of rejection blocker protects kidneys after transplant 3New type of rejection blocker protects kidneys after transplant 4Researchers track down cause of a disfiguring bone disorder 2Researchers track down cause of a disfiguring bone disorder 3Fragment of yellow fever virus may hold key to safer vaccine 2Fragment of yellow fever virus may hold key to safer vaccine 3
(Date:12/2/2009)... SINGAPORE, Dec. 2 S*BIO Pte Ltd t...l JAK2 inhibitor, SB1518, at The American Society ...n New Orleans. ,, Data will be presented on the... trial of SB1518 detailing its safety, tolerabilit...ile in dose levels ranging from 100 to 600 mg. The...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world ...in turmoil and uncertainty is part of many,busines...ndustry has been,relatively immune to the economic.... , During the midst of the difficult tim...p; Johnson inaugurated an R&D center in Shangh...
(Date:12/1/2009)...E VILLAGE, Nev., Dec. 1 ...nnounced revenue guidance for the fourth quarter e...n, as compared with $69 million for the fourth qua...lts was the first of two installment payments of $...h quarter 2008 results was a one-time $1.8 million...
(Date:12/1/2009)...UTH, Mass., Dec. 1 Harvest Technol...y results from the company sponsored 60-patient cl...Center in Chennai, India using the company,s BMAC ...Critical Limb Ischemia (CLI). Sri Ramachandra Medi...ciated institution based in Chennai, India and one...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...hat up to 30% of coffees ordered as "decaf&qu...now for sure with D+CAF, the first do-it-yourself ... leader in at-home water quality testing ( www.caf...ia, CA (PRWEB) November 12, 2008 -- Ever wonder wh...ecaf? Now you can know for sure with new D+CAF, t...
...E:,GSK) announced today that Gemstone Acquisition ...commencing a cash tender offer to purchase all,out...logies, Inc. (Nasdaq:,GNLB), for $1.30 in cash wit...xes. The tender offer is being made pursuant to a ...dated October 29, 2008 among Genelabs,Gemstone and...
...:,ADL), a vertically integrated pharmaceutical com...d today preliminary third quarter earnings and,rev...arter of FY2008, AMDL expects gross sales to be,ap...s promotions of,approximately $9.2 million. Gross ...n and income from operations to be approximately $...
Other Biology Technology:Is Your Decaf Really Decaf? Use New "D+CAF (tm) Caffeine Test Strips" to Know for Sure 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 3AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 2AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 3
...pathic effect inhibition assays, also known as CPE...ue culture supernatents; serum from PK studies and... is defined as the quantity of interferon required... viral infection by 50%. All standards used in o...
Topoisomerase I from Invitrogen
... type I eukaryotic topoisomerase that removes both...lled right- and left-handed supercoils) from coval... covalently closed, circular DNA with fewer positi...se I does not absolutely require Mg 2+ to functio...
Eco RII (Bst NI) from Roche Applied Science
Biology Products: